Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Blood (2017) 130 (Supplement 1): 4062.

https://doi.org/10.1182/blood.V130.Suppl_1.4062.4062

Published: 2017

Journal Articles

Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of Final FDG-PET in Diffuse Large B Cell Lymphoma Patients

Raffaella Marcheselli, PhD, Antonella Franceschetto, MD, Alessia Bari, MD, Luigi Marcheselli, MS, Tamar Tadmor, MD, Samantha Pozzi, MD, Ilana Levy, MD, Patrizia Pizzichini, MD, Daniela Prosperi, MD, Maria Christina Cox, MD, Rosaria D'Apollo, MD, Lucia Massi, MD, Napoleone Prandini, MD, Stefano Sacchi, MD

Blood (2017) 130 (Supplement 1): 1576.

https://doi.org/10.1182/blood.V130.Suppl_1.1576.1576

Published: 2017

Journal Articles

Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09)

Stefano Luminari, MD, Maria Cecilia Goldaniga, MD, Marina Cesaretti, Lorella Orsucci, Alessandra Tucci, MD, Alessandro Pulsoni, MD, Flavia Salvi, MD, Angelo Michele Carella, Alessandra Tedeschi, MD, Antonio Pinto, MD, Caterina Stelitano, Daniele Vallisa, MD, Fiorella Ilariucci, MD, Michele Spina, Luca Arcaini, Luigi Marcheselli, MS, Massimo Federico, MD, Luca Baldini

Blood (2013) 122 (21): 3049.

https://doi.org/10.1182/blood.V122.21.3049.3049

Published: 2013

Journal Articles

Are Absolute Monocyte Count and The Lymphocyte-Monocyte Ratio (LMR) Valid Prognostic Factors In Classical Hodgkin Lymphoma? An Evaluation Based On Data From 1079 Patients

Stefano Sacchi, MD, Alessia Bari, MD, Tamar Tadmor, MD, Luigi Marcheselli, MS, Samantha Pozzi, MD, Eliana Valentina Liardo, MD, Angela Ferrari, MD, Caterina Stelitano, Paolo G Gobbi, Prof, Luca Baldini, Daniele Vallisa, MD, Emilio Iannitto, MD, Aaron Polliack, MD, Massimo Federico

Blood (2013) 122 (21): 1754.

https://doi.org/10.1182/blood.V122.21.1754.1754

Published: 2013

Journal Articles

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Stefano Sacchi, MD, Samantha Pozzi, MD, Marina Cesaretti, Luigi Marcheselli, MS, Gabriele Buda, MD, Antonio Lazzaro, MD, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, MD, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, MD, Massimo Magagnoli, MD, Franco Silvestris, MD, Pier Paolo Fattori, MD, Patrizia Tosi, MD, Eliana Valentina Liardo, MD, Alessia Bari, MD, Angelo Michele Carella

Blood (2013) 122 (21): 4383.

https://doi.org/10.1182/blood.V122.21.4383.4383

Published: 2013

Journal Articles

Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.

Stefano Sacchi, Alessia Bari, MD, Tamar Tadmor, MD, Luigi Marcheselli, MS, Eliana Valentina Liardo, Samantha Pozzi, Stefano Luminari, MD, Luca Baldini, MD, Massimo Federico, MD, Aaron Polliack, MD

Blood (2012) 120 (21): 2647.

https://doi.org/10.1182/blood.V120.21.2647.2647

Published: 2012

Journal Articles

Secondary Leukemia After Non-Hodgkin Lymphoma: A Systematic Review and a Meta-Analysis

Raffaella Marcheselli, MS, Alessia Bari, MD, Eliana Valentina Liardo, MD, Luigi Marcheselli, MS, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2011) 118 (21): 5192.

https://doi.org/10.1182/blood.V118.21.5192.5192

Published: 2011

Journal Articles

Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bispohosphonates

Samantha Pozzi, MD, Raffaella Marcheselli, MS, Alessia Bari, MD, Eliana Valentina Liardo, MD, Paola Bresciani, MD, Maria Teresa Donini, MD, Santo Neri, MD, Luciano Masini, Giuseppe Caparrotti, MD, Pellegrino Musto, Elisa Ferraris, MD, Daniela Petro, MD, Luigi Marcheselli, MS, Antonio Palumbo, MD, Stefano Sacchi, MD

Blood (2011) 118 (21): 5134.

https://doi.org/10.1182/blood.V118.21.5134.5134

Published: 2011

Journal Articles

Relative Survival and Incidence Based Mortality of Diffuse Large B-Cell Lymphoma (DLBCL) in Rituximab Era: Population Based Study From Modena Cancer Registry (MCR)

Luigi Marcheselli, MS, Raffaella Marcheselli, MS, Alessia Bari, Claudia Cirilli, Eliana Valentina Liardo, MD, Samantha Pozzi, Massimo Federico, MD, Stefano Sacchi, MD

Blood (2011) 118 (21): 5185.

https://doi.org/10.1182/blood.V118.21.5185.5185

Published: 2011

Journal Articles

Secondary Malignancies after Treatment of Aggressive Non-Hodgkin Lymphoma: A GISL Cohort Study on 1259 Patients.

Stefano Sacchi, MD, Luigi Marcheselli, MS, Alessia Bari, MD, Raffaella Marcheselli, BS, Samantha Pozzi, MD, Giovanni Quarta, MD, Nicola Di Renzo, MD, Alberto Fragasso, MD, Francesco Angrilli, MD, Massimo Federico, MD

Blood (2007) 110 (11): 522.

https://doi.org/10.1182/blood.V110.11.522.522

Published: 2007

NARROW

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of Final FDG-PET in Diffuse Large B Cell Lymphoma Patients

Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09)

Are Absolute Monocyte Count and The Lymphocyte-Monocyte Ratio (LMR) Valid Prognostic Factors In Classical Hodgkin Lymphoma? An Evaluation Based On Data From 1079 Patients

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.

Secondary Leukemia After Non-Hodgkin Lymphoma: A Systematic Review and a Meta-Analysis

Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bispohosphonates

Relative Survival and Incidence Based Mortality of Diffuse Large B-Cell Lymphoma (DLBCL) in Rituximab Era: Population Based Study From Modena Cancer Registry (MCR)

Secondary Malignancies after Treatment of Aggressive Non-Hodgkin Lymphoma: A GISL Cohort Study on 1259 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only